Y Tameda, M Hamada, K Takase, T Nakano, Y Kosaka – 1 March 1996 – The cause of fulminant hepatic failure is reported to be unknown in more than half the cases in Japan. We recently reviewed 23 cases of fulminant hepatic failure that had been treated at our hospital. The cause of disease had been regarded as unknown before this study. It was found that seven of these patients had been under ecarazine hydrochloride therapy when they developed fulminant hepatic failure.

H Lin, M C Yang, M Hou, S Li, Y Huang, P Yu, Y Tsai, S Lee – 1 March 1996 – The hemodynamic effects of long‐term administration of octreotide in portal hypertension has not been established. In addition, whether long‐term octreotide treatment prevents the development of portosystemic shunts has not yet been evaluated. Hence, the current study was undertaken to evaluate the effects of long‐term administration of octreotide in rats with portal vein stenosis.

G D Schapiro, L S Friedman – 1 March 1996

Jean C. Emond, Scott D. Kelley, Thomas G. Heffron, Tomonori Nakagawa, John P. Roberts, Robert C. Lim – 1 March 1996 – Total vascular exclusion (TVE) of the liver is accomplished by complete occlusion of inflow and outflow of the liver during hepatectomy. It affords the opportunity for bloodless, anatomically precise parenchymal transection but has not been widely used in this country. TVE should make it possible to treat large or unfavorably located lesions safely. To evaluate the benefit of this modality, we have examined the results of TVE in 49 major resections.

Christine M. Hunt, Julie S. Tart, Elaine Dowdy, Barbara Philips Bute, Diane M. Williams, Pierre‐Alain Clavien – 1 March 1996 – Employment, functional status, health status, and prevalence of anxiety and depression were assessed in patients who had undergone orthotopic liver transplantation at Duke University from 1984 to 1993 to identify social and economic factors that might influence return to work after liver transplantation. Patients were asked to complete mailed questionnaires. A transplant nurse coordinator assigned patients a Karnofsky score, unaware of the questionnaire responses.

1 March 1996

Norah A. Terrault, Connie Combs Holland, Linda Ferrell, Judith A. Hahn, John R. Lake, John P. Roberts, Nancy L. Ascher, Teresa L. Wright – 1 March 1996 – Reinfection with hepatitis B virus (HBV) after liver transplantation is nearly universal in patients not receiving immunoprophylaxis. Because reinfection reduces graft and patient survival, treatment of recurrent infection is important. Interferon alfa (IFN‐α) is an effective therapy for chronic hepatitis B infection in immunocompetent patients, but its efficacy in transplant recipients has not been established.

O Farges, F Saliba, H Farhamant, D Samuel, A Bismuth, M Reynes, H Bismuth – 1 February 1996 – A retrospective analysis was undertaken to determine if the incidence, timing, and severity of acute and chronic rejection were influenced by the primary disease necessitating transplantation. Of the 875 liver transplantations performed between 1984 and 1992, 768 were primary transplantations and 107 were retransplantations.

P J O'Connor, K W Southern, I M Bowler, H C Irving, P J Robinson, J M Littlewood – 1 February 1996 – This was a prospective open study that examined the quantitative and qualitative analysis of hepatobiliary scintigraphy (DISIDA) in detecting liver involvement in cystic fibrosis (CF).

S Zeuzem, J M Schmidt, J Lee, B Ruster, W K Roth – 1 February 1996 – In about 30% to 40% of patients with chronic hepatitis C, treatment with recombinant interferon alfa (r‐IFNα) causes a decrease of serum aminotransferases and hepatitis C virus (HCV) RNA. The antiviral mechanism of interferon alfa (IFNα) in vivo is unknown. From serial measurements of serum HCV‐RNA concentrations following IFNα induced perturbation of the balance between virus production and clearance, we obtained kinetic information on the pretreatment steady‐state of HCV.